Indications for: RECARBRIO
Susceptible infections including hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP); complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), including pyelonephritis in those who have limited or no alternative treatment options.
Give by IV infusion over 30mins. ≥18yrs: 1.25g every 6hrs. Duration of therapy: 4–14 days (based on severity or location of infection). Renal impairment (CrCl 60–89mL/min): 1g every 6hrs; (CrCl 30–59mL/min): 0.75g every 6hrs; (CrCl 15–29mL/min) or (ESRD on hemodialysis): 0.5g every 6hrs; (CrCl <15mL/min): not recommended unless hemodialysis is started within 48hrs. Hemodialysis: give after session (see full labeling).
<18yrs: not established.
Discontinue immediately if hypersensitivity reaction occurs. Compromised renal function. CNS disorders (eg, brain lesions, history of seizures). Perform neurological evaluation if CNS reactions (eg, seizures, confusional states, myoclonic activity) occur. Risk of C. difficile-associated diarrhea; discontinue and treat if colitis is suspected or confirmed. Elderly. Pregnancy. Nursing mothers.
Carbapenem (thienamycin) + dehydropeptidase I inhibitor + beta-lactamase inhibitor.
Avoid concomitant valproic acid or divalproex sodium; consider alternatives other than carbapenems. Concomitant ganciclovir: not recommended.
Diarrhea, nausea, headache, vomiting, ALT/AST increased, phlebitis/infusion site reactions, pyrexia, hypertension, anemia, hypokalemia, hyponatremia; CNS reactions, C. difficile-associated diarrhea.
Generic Drug Availability: